SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Collection of ethnicity data in clinical research has been poor historically, but is essential to ensure that interventions are effective and safe across diverse populations. These data are needed to ...

While we have commonly heard of common side effects of weight loss jabs such as nausea and constipation, there is a new concern that experts are highlighting and users are discussing across support ...

More scientific evidence is emerging to show that our gastrointestinal system interacts with our nervous system ...

Regarding injection site rotation, alternate between different areas like the abdomen, thigh, or upper arm to prevent ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

As weight loss jabs like Ozempic and Wegovy become ever more popular, doctors are growing increasingly concerned about their gnarly side effects. As Germany's Deutsche Welle notes, people who take ...

GLP-1 is a hormone that regulates blood sugar, appetite and digestion. A diet rich in high-fiber foods may help your body ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...